Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multidrug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged. A change in paradigm emerges from the availability of the HapMap, the wealth of data on less-common genetic polymorphisms, and new genotyping technology. This review presents a comprehensive analysis of the existing literature on pharmacogenetic determinants of antiretroviral drug exposure, drug toxicity, as well as genetic markers associated with the rate of disease progression. It is expected that larger-scale comprehensive genome approaches will profoundly change the landscape of knowledge in the future.

中文翻译：

---

抗HIV药物的药理学。

由于长期使用多种药物疗法的复杂性和潜在毒性，药物遗传学在HIV治疗中具有广阔的前景。迄今为止，很少检查候选基因的有限等位基因变体，但是已经出现了许多已证实的关联。HapMap的可用性，不常见的遗传多态性的大量数据以及新的基因分型技术使范式发生了变化。这篇综述对有关抗逆转录病毒药物暴露，药物毒性以及与疾病进展速度相关的遗传标志物的药物遗传学决定因素的现有文献进行了全面分析。可以预期，大规模的综合基因组方法将在未来深刻地改变知识的面貌。